{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:42:59Z","timestamp":1776660179663,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.10.048","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T05:50:29Z","timestamp":1637128229000},"page":"7357-7362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12\u201313 February 2020"],"prefix":"10.1016","volume":"39","author":[{"given":"Gerald","family":"Voss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne-Marie","family":"Jacquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Tornieporth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Karron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajoke Sobanjo-ter","family":"Meulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lurie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Weller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob P.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Saville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Darko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.10.048_b0005","unstructured":"World Health Organization. WHO Research and Development Blueprint. Annual review of diseases prioritized under the Research and Development Blueprint: Informal consultation [Internet]. Geneva:WHO;2018. Available from: https:\/\/www.who.int\/docs\/default-source\/blue-print\/2018-annual-review-of-diseases-prioritized-under-the-research-and-development-blueprint.pdf?sfvrsn=4c22e36_2."},{"key":"10.1016\/j.vaccine.2021.10.048_b0010","doi-asserted-by":"crossref","unstructured":"Modi N, Ayres-de-Campos D, Bancalari E, Benders M, Briana D, Di Renzo GC et al. Equity in coronavirus disease 2019 vaccine development and deployment. American Journal of Obstetrics & Gynecology May 2021: 423-427; https:\/\/doi.org\/10.1016\/j.ajog.2021.01.006.","DOI":"10.1016\/j.ajog.2021.01.006"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.048_b0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/healthcare8040511","article-title":"Maternal coronavirus infections and neonates born to mothers with SARS-CoV-2: a systematic review","volume":"8","author":"Amaral","year":"2020","journal-title":"Healthcare (Basel)."},{"key":"10.1016\/j.vaccine.2021.10.048_b0020","unstructured":"NCT04754594. Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04754594?term=vaccine+pregnant+women&cond=COVID-19&draw=2&rank=2."},{"key":"10.1016\/j.vaccine.2021.10.048_b0025","doi-asserted-by":"crossref","unstructured":"Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010;63(6):425\u201333.","DOI":"10.1111\/j.1600-0897.2010.00836.x"},{"issue":"7","key":"10.1016\/j.vaccine.2021.10.048_b0030","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S1473-3099(17)30229-3","article-title":"Maternal immunisation: collaborating with mother nature","volume":"17","author":"Marchant","year":"2017","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"10.1016\/j.vaccine.2021.10.048_b0035","first-page":"53","article-title":"Tetanus vaccines position paper","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"47","key":"10.1016\/j.vaccine.2021.10.048_b0040","first-page":"461","article-title":"Influenza vaccines position paper","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"issue":"35","key":"10.1016\/j.vaccine.2021.10.048_b0045","first-page":"433","article-title":"Pertussis vaccines: WHO position paper","volume":"90","author":"World Health Organization","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2021.10.048_b0050","unstructured":"World Health Organization. Yellow Fever [Internet]. Available from: https:\/\/afro.who.int\/health-topics\/yellow-fever. [Accessed February 4, 2021]."},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.048_b0055","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/21645515.2017.1356525","article-title":"Safety of oral cholera vaccines during pregnancy in developing countries","volume":"13","author":"Khan","year":"2017","journal-title":"Hum Vaccin Immunother."},{"issue":"29","key":"10.1016\/j.vaccine.2021.10.048_b0060","first-page":"329","article-title":"Meningococcal A conjugate vaccine during pregnancy","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2021.10.048_b0065","doi-asserted-by":"crossref","first-page":"i102","DOI":"10.1093\/ije\/dyq027","article-title":"Tetanus toxoid immunization to reduce mortality from neonatal tetanus","volume":"39","author":"Blencowe","year":"2010","journal-title":"Int J Epidemiol."},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.048_b0070","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1080\/21645515.2017.1321722","article-title":"Influenza vaccine effectiveness among high-risk groups: a systematic literature review and meta-analysis of case-control and cohort studies","volume":"14","author":"Restivo","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.vaccine.2021.10.048_b0075","doi-asserted-by":"crossref","unstructured":"Campbell H, Gupta S, Dolan GP, et al. Review of vaccination in pregnancy to prevent pertussis in early infancy. J Med Microbiol. 2018;67:1426\u201356.","DOI":"10.1099\/jmm.0.000829"},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.048_b0080","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1473-3099(16)30523-0","article-title":"Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study","volume":"17","author":"Ali","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2021.10.048_b0085","series-title":"Safety of immunization during pregnancy","author":"WHO Global Advisory Committee on Vaccine Safety","year":"2014"},{"key":"10.1016\/j.vaccine.2021.10.048_b0090","unstructured":"Nigeria Centre for Disease Control. An update of Lassa fever outbreak in Nigeria. Available from: https:\/\/www.ncdc.gov.ng\/diseases\/sitreps\/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria. [Accessed February 4, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.048_b0095","unstructured":"WHO Lassa fever. Available from: https:\/\/www.who.int\/health-topics\/lassa-fever#tab=tab_1. [Accessed September 17, 2021]."},{"issue":"8","key":"10.1016\/j.vaccine.2021.10.048_b0100","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3201\/eid2508.181299","article-title":"Retrospective cohort study of Lassa fever in pregnancy","volume":"25","author":"Okogbenin","year":"2019","journal-title":"Southern Nigeria. Emerg Infect Dis."},{"key":"10.1016\/j.vaccine.2021.10.048_b0105","unstructured":"Center for Disease Control and Prevention (CDC). Women with smallpox vaccine exposure during pregnancy reported to the National Smallpox Vaccine in Pregnancy Registry --- United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:386-88."},{"key":"10.1016\/j.vaccine.2021.10.048_b0110","doi-asserted-by":"crossref","unstructured":"Munoz FM, Swamy GK, Hickman SP, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. 2019;220(11):1802-15.","DOI":"10.1093\/infdis\/jiz390"},{"key":"10.1016\/j.vaccine.2021.10.048_b0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.vaccine.2019.01.011","article-title":"Pregnant women and vaccines against emerging epidemic threats: ethics guidance for preparedness, research, and response","volume":"39","author":"Krubiner","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.10.048_b0120","unstructured":"Brighton Collaboration. Benefit-Risk Assessment of Vaccines by TechnolOgy (BRAVATO; ex-V3SWG) [Internet]. Available from: https:\/\/brightoncollaboration.us\/bravato\/."},{"key":"10.1016\/j.vaccine.2021.10.048_b0125","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline: Detection of reproductive and developmental toxicity for human pharmaceuticals S5(R3). Geneva:ICH;2020. Available from: https:\/\/database.ich.org\/sites\/default\/files\/S5-R3_Step4_Guideline_2020_0218.pdf."},{"key":"10.1016\/j.vaccine.2021.10.048_b0130","series-title":"ICH S5 (R3) guideline on reproductive toxicology: Detection of toxicity to reproduction for human pharmaceuticals - step 5","author":"European Medicines Agency","year":"2020"},{"key":"10.1016\/j.vaccine.2021.10.048_b0135","series-title":"Draft Guidance: Detection of toxicity to reproduction for human pharmaceuticals","author":"US Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.vaccine.2021.10.048_b0140","unstructured":"World Health Organization. WHO Guidelines on the nonclinical evaluation of vaccines. WHO Technical Report Series No. 927, Annex 1. [Internet]. Geneva:WHO;2005. Available from: https:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/nonclinical_evaluation\/ANNEX%201Nonclinical.P31-63.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2021.10.048_b0145","doi-asserted-by":"crossref","unstructured":"Kochhar S, Bauwens J, Bonhoeffer J. Safety assessment of immunization in pregnancy. Vaccine 2017;35(48 Pt A):6469\u201371.","DOI":"10.1016\/j.vaccine.2017.09.033"},{"issue":"26","key":"10.1016\/j.vaccine.2021.10.048_b0150","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.vaccine.2020.01.017","article-title":"Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries, Dakar, 10\u201311 September 2019","volume":"38","author":"Salami","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.048_b0155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40475-019-00190-1","article-title":"When is it acceptable to vaccinate pregnant women? Risk, ethics, and politics of governance in epidemic crises","volume":"6","author":"Graham","year":"2019","journal-title":"Curr Trop Med Rep."},{"key":"10.1016\/j.vaccine.2021.10.048_b0160","doi-asserted-by":"crossref","unstructured":"Jackson LA, Patel SM, Swamy GK, et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis. 2011;204:854\u201363.","DOI":"10.1093\/infdis\/jir440"},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.048_b0165","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2021.10.048_b0170","unstructured":"NCT04152486, Effectiveness and safety of a heterologous, two-dose Ebola vaccine in the DRC. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04152486?term=NCT04152486&draw=2&rank=1 [Accessed February 4, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.048_b0175","unstructured":"NCT04556526, A study of a two-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy pregnant women. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=NCT04556526&cntry=&state=&city=&dist= [Accessed February 4, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.048_b0180","unstructured":"NCT04032093, A Phase 2b placebo-controlled, randomized study of a respiratory syncytial virus (RSV) vaccine in pregnant women. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04032093?term=NCT04032093&draw=2&rank=1 [Accessed February 4, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.048_b0185","unstructured":"Perinatal Society of Australia and New Zealand. Interdisciplinary Maternal Perinatal Australasian Collaborative Trials Network (IMPACT). Available from: https:\/\/impact.psanz.com.au\/research\/ [Accessed December 9, 2020]."},{"issue":"49","key":"10.1016\/j.vaccine.2021.10.048_b0190","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1016\/j.vaccine.2016.08.026","article-title":"Obstetrical and neonatal case definitions for immunization safety data","volume":"34","author":"Chen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.10.048_b0195","doi-asserted-by":"crossref","unstructured":"Stuurman AL, Riera M, Lamprianou S, et al. Vaccine safety surveillance in pregnancy in low- and middle-income countries using GAIA case definitions: a feasibility assessment. Vaccine 2018;36 6736-43.","DOI":"10.1016\/j.vaccine.2018.09.033"},{"issue":"22","key":"10.1016\/j.vaccine.2021.10.048_b0200","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1016\/j.vaccine.2019.03.074","article-title":"Immunization in pregnancy safety surveillance in low- and middle-income countries- field performance and validation of novel case definitions","volume":"37","author":"Kochhar","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.10.048_b0205","unstructured":"Global Alliance to Prevent Prematurity and Stillbirth. Maternal immunization safety monitoring in low- and middle-income countries. A roadmap for programme development. Seattle, WA: GAPPS; 2017. Available from: https:\/\/www.gapps.org\/PDF\/MaternalImmunizationSafetyMonitoringInLMICs.pdf."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:04:42Z","timestamp":1759403082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21013827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21013827"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12\u201313 February 2020","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}